TrialTargeted oncology2024

Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer.

Yu Sunakawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.